ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
about
Irinotecan pharmacogenomicsSynthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance proteinGenome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cellsPregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsOncogene-specific formation of chemoresistant murine hepatic cancer stem cells.Deciphering cellular states of innate tumor drug responses.Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models.The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.ABCG2 expression, function, and promoter methylation in human multiple myelomaMolecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.Pharmacogenetics of irinotecan toxicity.Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.Contribution of tumoral and host solute carriers to clinical drug response.Role of the breast cancer resistance protein (ABCG2) in drug transport.Pharmacogenetics of colorectal cancer.Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.Cell-selective biological activity of rhodium metalloinsertors correlates with subcellular localizationABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.Oligomerization of human ATP-binding cassette transporters and its potential significance in human disease.mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Human ABCG2: structure, function, and its role in multidrug resistance.Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoFOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2.A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
P2860
Q28287024-E605AF8B-6F92-4E8A-B371-2824FACE2D5EQ30439828-098EE107-97E5-4106-98CF-CC231A8CED22Q33565717-20C9A85D-07CE-46D9-BA80-629A618DBA0BQ33728760-9767A18C-D87B-4F00-A7CE-3A3579F109EFQ34008793-234BBF70-12BC-4037-BE2F-D44FAE0087AAQ34233172-D07D7234-1AEC-4290-97D3-8AF927D30668Q35012940-FF7A91AF-E71C-4028-811E-134930D4B94AQ35067898-C5221512-4B1F-46DB-9375-5E0D840ECD7FQ35171274-847E548E-8C54-4B0D-B9C3-009BC4838B13Q35190691-6059DA42-6858-4ED6-BAF3-551E5A6D8C4FQ35595044-9DC69948-4F91-46C6-AE90-66F8C96EA342Q35609161-4F8571F2-0564-49BF-AE07-4FA7A842EBCEQ35793641-76F0E8F5-2A58-4501-BA07-9421089C9581Q35832549-9E895309-B434-43BB-B854-0AE47E636756Q35848835-601825C7-796C-4A7B-9E44-AD9EA041CEE0Q35902206-83D1C933-B411-4F00-A277-D4F502ACE7DCQ35911147-9AE711E3-B8D2-454C-BFCD-FCCB1DD18205Q35919726-0C3B9120-B792-4593-A0EA-089584A78504Q35946876-B46F7F5A-2386-40E8-B973-2BFD9505BB03Q36250753-31BFBE2C-D46F-41FD-8046-00DE34EB0BD8Q36326214-3FBD042F-0152-4F50-8E19-DBF0EEC78E66Q36556926-551C20E9-6F16-4A57-ACC3-7D73FE4DC772Q36629578-796CD0A8-6A03-40ED-B568-EA82AAA0FA71Q36788481-61D42ACD-5535-45E5-A39D-1A9BACA680E6Q36838947-15C98FBF-E131-4A49-8889-98E69D9E926BQ36935258-6B3E3213-BE75-4BB0-9BA9-71CC39B32AF4Q37087781-7E941655-70C1-4C26-8A4F-046D40A6495AQ37287637-F2A9F665-E8F5-4156-A8EF-3DF0069A87CDQ37563366-B8A26E80-E883-4DB9-A65B-1F6865BA56C9Q37564553-1DFDFE25-03D4-4917-9A04-9798EE087BBEQ37610090-430590F6-513D-45CB-8B20-90D26E297AF2Q37923365-53766E56-0060-40CB-8D76-EC0B0AA5A4EBQ37958162-7E8C9BB7-93B1-436A-98FF-B59AC4FC5EE5Q38003156-5BBF28B8-67AB-4CBD-9807-EAD9DB88BEF0Q38540360-CA67A7E0-5DDB-40DA-B58B-DBDD9CB93C88Q38710502-2A76335C-8C84-4E8E-B7B5-5AC4188B44EEQ38743209-A2927211-DDF9-4B14-AC5D-5B8B81E41165Q38759264-F9B4CEA7-B468-4FD5-8271-7B427730BE1BQ38767018-A881442D-B847-4170-861D-58947C31C518Q38901400-A12F514F-3615-4848-9BC0-815E39C4596B
P2860
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
ABCG2 overexpression in colon ...... irinotecan-treated metastases.
@en
type
label
ABCG2 overexpression in colon ...... irinotecan-treated metastases.
@en
prefLabel
ABCG2 overexpression in colon ...... irinotecan-treated metastases.
@en
P2093
P356
P1476
ABCG2 overexpression in colon ...... irinotecan-treated metastases
@en
P2093
Beatrice Orsetti
Bernard Pau
Delphine Peyron
Frederic Bibeau
George L Scheffer
Isabelle Gourdier
Laurent Candeil
Maguy Del Rio
Nadia Vezzio
Qasim A Khan
P304
P356
10.1002/IJC.20032
P577
2004-05-01T00:00:00Z